Process of purification of protein
The invention provides a process of purification of antibody or fusion protein from protein mixture comprising product and process related impurities. The process provides the use of hydroxyapatite chromatography for the separation of low molecular weight impurities and basic variants. In addition, invention further provides a scalable purification process to remove product and process related impurities.
1. A process of purifying a protein of interest from a protein mixture comprising the protein of interest and one or more basic variants, the process comprising:
a) loading the protein mixture onto a ceramic hydroxyapatite column with a loading buffer;
b) washing the ceramic hydroxyapatite column with a washing buffer;
c) eluting by a linear gradient with an eluting buffer, thereby producing an eluted protein mixture comprising a purified protein of interest;
wherein the washing buffer is sodium phosphate buffer;
wherein the eluting buffer is sodium phosphate buffer; and
wherein the purified protein of interest is substantially pure and the one or more basic variants are present in the eluted protein mixture in an amount below 15% as analysed by cation exhange high performance liquid chromatography.
2. The process of claim 1 , wherein the one or more basic variants are present in the eluted protein mixture in an amount of about 14% or less.
3. The process of claim 1 , wherein the linear gradient with the eluting buffer comprises a phosphate concentration from about 24 mM to about 104 mM.
4. The process of claim 3 , wherein the phosphate concentration is increased gradually from about 40 mM to about 96 mM.
5. The process according to claim 1 , wherein the linear gradient with the eluting buffer is a linear gradient wherein the phosphate concentration is increased gradually from about 10% to about 24%.
6. The process of claim 1 , wherein eluting by the linear gradient with the eluting buffer is performed for 19 CV.
7. The process of claim 1 , wherein eluting by the linear gradient with the eluting buffer starts at an ascending value of about 1.5 AU/cm and ends at a descending value of about 1.5 AU/cm.
8. The process of claim 1 , wherein eluting by the linear gradient with the eluting buffer starts at an ascending value of about 1.0 AU/cm and ends at a descending value of about 1.5 AU/cm.
9. The process of claim 1 , wherein the loading buffer has same conductivity and pH as the washing buffer.
10. The process of claim 1 , wherein each of the loading buffer, the washing buffer, and the eluting buffer has pH 7.0±0.2.
11. The process of claim 1 , wherein each of the loading buffer, the washing buffer, and the eluting buffer does not have any additives selected from sodium chloride, calcium chloride, and glycine.
12. The process of claim 1 , wherein the protein of interest is an IgG1 antibody which binds to IgE.
13. The process of claim 12 , wherein the IgG1 antibody is omalizumab.
14. The process of claim 1 , wherein the purified protein of interest comprises a reduced amount of the one or more basic variants by at least 95% as measured by cation exchange high performance liquid chromatography analysis.
15. A pharmaceutical composition comprising omalizumab and one or more basic variants, wherein the pharmaceutical composition comprises the one or more basic variants in an amount of about 14% or less as measured by cation exchange high performance liquid chromatography analysis; and wherein the pharmaceutical composition has omalizumab purity of at least 90%.
16. The pharmaceutical composition as claimed in claim 15 , wherein the pharmaceutical composition has omalizumab purity of more than 90%.
17. The pharmaceutical composition as claimed in claim 16 , wherein the pharmaceutical composition has omalizumab purity of more than 95%.
18. The pharmaceutical composition as claimed in claim 17 , wherein the pharmaceutical composition has omalizumab purity of more than 99%.
19. The pharmaceutical composition as claimed in claim 15 , wherein the pharmaceutical composition comprises the one or more basic variants in an amount of about 10% or less as measured by cation exchange high performance liquid chromatography analysis.
20. The pharmaceutical composition as claimed in claim 15 , wherein the pharmaceutical composition has omalizumab purity of at least 90% as measured by size exclusion high performance liquid chromatography.
21. The process of claim 2 , wherein the one or more basic variants are present in the eluted protein mixture in an amount of about 10%.